ArticleProceedings of the National Academy of Sciences of the United States of America2008
Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 142 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
142 citing papers in PubMed, 2 syntheses or guidelines pooled it, 275 citations in OpenAlex.
- Cumulative evidence for associations between genetic variants in interleukin 17 family gene and risk of human diseases.Frontiers in immunology · 2022Pooled it
- The prognostic value of interleukin-17 in lung cancer: A systematic review with meta-analysis based on Chinese patients.PloS one · 2017Pooled it
- Interleukin-6 as a therapeutic target in human ovarian cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2011Trial
- Soluble CD14 promotes Th17 expansion and differentiation through gamma-aminobutyric acid and expands infidel innate lymphoid cells.PNAS nexus · 2026Article
- The intrinsic expression of NLRP3 in Th17 cells promotes their protumor activity and conversion into Tregs.Cellular & molecular immunology · 2025Article
- Characterization of immune landscape and prognostic value of IL-17-related signature in invasive breast cancer.Translational cancer research · 2025Article
- Expression of interleukin-17 in oral tongue squamous cell carcinoma and its effect on biological behavior.Scientific reports · 2025Article
- A novel Tc17 population recruited by tumor cells promotes tumor progression in gastric cancer.Frontiers in oncology · 2025Article
- Stage-dependent EZH2 methylation correlates with immune polarization, metabolic suppression, and unfavorable outcomes in hepatocellular carcinoma.International journal of medical sciences · 2025Article
- Identification of hypoxia-related diagnostic biomarkers and immune signatures in diminished ovarian reserve.Frontiers in genetics · 2025Article
- Remodeling of immune system functions by extracellular vesicles.Frontiers in immunology · 2025Article
- Article
- Current and future immunotherapeutic approaches in pancreatic cancer treatment.Journal of hematology & oncology · 2024Review
- Reciprocal crosstalk between Th17 and mesothelial cells promotes metastasis-associated adhesion of ovarian cancer cells.Clinical and translational medicine · 2024Article
- T cells in health and disease.Signal transduction and targeted therapy · 2023Review
- Application of single-cell RNA sequencing analysis of novel breast cancer phenotypes based on the activation of ferroptosis-related genes.Functional & integrative genomics · 2023Article
- Mechanism underlying the action of Duanteng-Yimu Tang in regulating Treg/Th17 imbalance and anti-rheumatoid arthritis.Heliyon · 2023Article
- Intestinal flora plays a role in the progression of hepatitis-cirrhosis-liver cancer.Frontiers in cellular and infection microbiology · 2023Review
- PLAC8 is an innovative biomarker for immunotherapy participating in remodeling the immune microenvironment of renal clear cell carcinoma.Frontiers in oncology · 2023Article
- Activation of the IL-17 signalling pathway by the CXCL17-GPR35 axis affects drug resistance and colorectal cancer tumorigenesis.American journal of cancer research · 2023Article
82 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the important role of Th17 cells in the pathogenesis of many autoimmune diseases, their prevalence and the mechanisms by which they are generated and regulated in cancer remain unclear. Here, we report the presence of a high percentage of CD4(+) Th17 cells at sites of ovarian cancer, compared with a low percentage of Th17 cells in peripheral blood mononuclear cells from healthy donors and cancer patients. Analysis of cytokine production profiles revealed that ovarian tumor cells, tumor-derived fibroblasts, and antigen-presenting cells (APCs) secreted several key cytokines including IL-1beta, IL-6, TNF-alpha and TGF-beta, which formed a cytokine milieu that regulated and expanded human IL-17-producing T-helper (Th17) cells. We further show that IL-1beta was critically required for the differentiation and expansion of human Th17 cells, whereas IL-6 and IL-23 may also play a role in the expansion of memory Th17 cells, even though IL-23 levels are low or undetectable in ovarian cancer. Further experiments demonstrated that coculture of naïve or memory CD4(+) T cells with tumor cells, APCs, or both could generate high percentages of Th17 cells. Treatment with anti-IL-1 alone or a combination of anti-IL-1 and anti-IL-6 reduced the ability of tumor cells to expand memory Th17 cells. Thus, we have identified a set of key cytokines secreted by ovarian tumor cells and tumor-associated APCs that favor the generation and expansion of human Th17 cells. These findings should accelerate efforts to define the function of this important subset of CD4(+) T cells in the human immune response to cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.